Background and purpose: It is widely acknowledged that individual response to antiepileptic drugs (AEDs) is influenced by genetic factors. However, most of the underlying genes and genetic variants remain unidentified to date. The purpose of this study is to examine the role of common variants in a number of candidate genes in the response to commonly prescribed AEDs. Methods: We recruited 495 patients with epilepsy. Patients were classified according to their response to several AEDs. We genotyped 104 polymorphisms in 17 candidate genes for AED response. We looked for statistically significant associations between these polymorphisms and well-defined AED response phenotypes. Results: We identified significant associations of CYP2C9 variant alleles with presence of phenytoin (PHT) adverse drug reactions (ADRs) and of GSTM1 copy number variation with the presence of carbamazepine ADRs. The latter association could not be confirmed in a replication study. Conclusions: Our study is the first comprehensive candidate gene association study in epilepsy pharmacogenetics. Our results confirm the role of CYP2C9 variants in PHT toxicity. No other definite associations were identified. Large-scale efforts are needed to unravel the genetic determinants of AED response.
Introduction
It is well known that genetic variants may contribute significantly to interindividual differences in response to drugs. Pharmacogenetic studies in different disease domains have provided some robust examples of genetic variants influencing drug response. Some of these findings have important clinical consequences, and a number have been translated into clinical tests [1, 2] . Although epilepsy is one of the commonest neurological disorders and large differences in response to antiepileptic drugs (AEDs) are well recognized, the field of epilepsy pharmacogenetics has remained largely unexplored up to date. A number of studies have looked at one or a few candidate genes [3] , but unlike in several other common diseases, large-scale studies in epilepsy pharmacogenetics are lacking. A number of genetic associations have been reported [4] , but only one finding has resulted in clinical application so far:
HLA-B*1502 testing is recommended before starting carbamazepine (CBZ) therapy in individuals of Asian ancestry [5] .
Although for many AEDs the exact mechanisms of action have not been elucidated, considerable progress has been made in our understanding of the pathways involved in metabolism and mechanism of action for several AEDs. Therefore, it is possible to draft a list of plausible candidate genes for epilepsy pharmacogenetics. These include mainly genes encoding AED transporters, drug-metabolizing enzymes (DMEs) and AED targets [6] . The aim of our study was to perform a comprehensive screening of common variation in a number of biologically plausible candidate genes in relation to response to commonly prescribed AEDs.
Methods

Patients and phenotyping
Four hundred and ninety-five adult patients with a diagnosis of epilepsy according to ILAE criteria were included from two tertiary referral centres in Belgium (Hoˆpital Erasme, Brussels, and Universitair Ziekenhuis Gasthuisberg, Leuven). A breakdown of recruited patients is given in Fig. S1 . The study was approved by the relevant institutional Ethics Committees. All patients provided written informed consent.
Clinical data were extracted from medical records and entered in a web-based clinical database. PatientsÕ ethnic group was determined based on the country of origin of the four grandparents. Most patients were on AED polytherapy. For each patient, the following clinical data were recorded: (i) presence or absence of any adverse drug reaction (ADR) attributed by the clinician to CBZ, sodium valproate (VPA) and phenytoin (PHT) therapy, (ii) efficacy of VPA and (iii) overall efficacy of AEDs with a major action on sodium channels. Patients in whom start-and stopdates of a particular AED were unknown were excluded from the ADR analysis, unless specific info on ADRs was available in the patientÕs medical records. Patients were classified as refractory to VPA if either VPA was stopped because of inefficacy or seizure frequency did not change or increased within 6 months after starting VPA. Patients were classified as sensitive to VPA if either VPA was stopped for another defined reason than inefficacy or VPA was continued and a ‡ 50% decrease in seizure frequency within 6 months after starting VPA and lasting for ‡3 months was documented. Cases that were exposed to VPA for <3 months, cases in which another AED was started before the decrease in seizure frequency occurred and cases that had had epilepsy surgery were excluded. Patients were classified as overall AED refractory if they had received non-medical treatment (neurosurgery, radiosurgery, vagal nerve stimulation) for refractory epilepsy and had tried at least two AEDs acting on sodium channels. Patients who had been considered for epilepsy surgery but did not subsequently go on to have surgery were also included. Patients were classified as overall AED sensitive if they had been seizure free for at least a year and were treated with at least one AED acting on sodium channels at last follow-up. AEDs considered to have a major action on sodium channels were CBZ, PHT, lamotrigine, oxcarbazepine and topiramate.
The replication cohort consisted of 817 patients with epilepsy recruited from the epilepsy clinics at Duke University (US). In this cohort, absence of ADRs on CBZ was defined as no reported ADRs and duration of CBZ treatment of at least a year and/or a maintenance dose of CBZ was recorded.
Genotyping DNA was extracted from lymphocytes according to standard procedures. We genotyped 102 single nucleotide polymorphisms (SNPs) covering 16 candidate genes. These genes include EPHX1, GSR, GSS, GSTA3, GSTA4, GSTA5, GSTM3, GSTM4, SCN1A, SCN2A, SCN3A, SCN8A, UGT1A6, UGT2B7, CYP2A6 and CYP2C9 (Table 1) . SNPs were selected based either on (putative) functional properties or on haplotype tagging properties. Tagging SNPs (tSNPs) were selected from the International HapMap [7] using pairwise tagging with a minor allele frequency cut-off of 0.05 and an r 2 cut-off of 0.8. The majority of SNPs were genotyped using SNPlex technology (Applied Biosystems, Foster City, CA, USA). Ten SNPs were typed using different low throughput genotyping techniques. Additionally, copy number variants (CNV) of CYP2A6 and GSTM1 were typed using TaqMan technology (Applied Biosystems).
Statistical analysis
We searched for allelic, genotypic and haplotypic associations between the following genes and phenotypes (Table 1) : (i) EPHX1 and CBZ ADRs; (ii) GSS, GSR, GSTA3, GSTA4, GSTA5, GSTM3, GSTM4, UGT1A6, UGT2B7, CYP2A6, CYP2C9 and VPA ADRs and efficacy; (iii) SCN1A, SCN2A, SCN3A, SCN8A and overall AED efficacy; (iv) CYP2C9 and PHT ADRs; (v) GSTM1 and CBZ ADRs. We used the SNPassoc package [8] for statistical analysis. All SNPs were checked for deviation from Hardy-Weinberg equilibrium. Each association was assessed considering the following five genetic models: additive, co-dominant, dominant, recessive and over-dominant. For each gene, we also performed an analysis at the haplotype level. For the CYP2C9 and CYP2A6 association analyses, we considered three patient categories: (i) extensive metabolizers: homozygotes for the major allele at both loci, (ii) intermediate metabolizers: heterozygotes for either one of the two loci and (iii) poor metabolizers: homozygotes for the minor allele for at least one of the two loci and double heterozygotes. All models were adjusted for age and gender. For each gene, we corrected for the number of polymorphisms tested, considering an experiment-wide type I error rate of 0.05.
Results
PatientsÕ mean age was 45 ± 15 years. Two hundred and twenty-nine were men and 266 women. All patients were of Caucasian origin (Table S1) AED response candidate gene study the different ADR types per AED is given in Table 2 . Eighty-three patients were classified refractory to VPA and 94 sensitive. Hundred and twenty-eight patients were classified overall AED refractory and 88 overall AED sensitive. In the replication cohort, 451 patients were treated with CBZ, of which 143 reported ADRs and 163 reported no ADRs. Genotyping of seven SNPs (rs7496, rs1010167, rs17838158, rs12151636, rs13397210, rs17183814 and rs2028364,) failed. After Bonferroni correction for multiple comparisons, four SNPs were out of HardyWeinberg equilibrium (rs17614751, rs17614871, rs3757918 and rs2281594). These were discarded from the analysis. Therefore, the final analysis included 91 SNPs and two CNVs.
After correction for multiple comparisons, two associations remained significant (Tables 3, 4 and S2): CYP2C9*2 and *3 alleles and PHT ADRs (P c 0.008); and GSTM1 CNV and CBZ ADRs (P c 0.009). Replication of the association of GSTM1 CNV with CBZ ADRs in the second patient cohort failed to show a significant association (P c 0.54, results not shown).
Discussion
The aim of this study was to conduct a targeted pharmacogenetic study of commonly used AEDs in an accurately phenotyped cohort of patients with epilepsy. To our knowledge, the current study is the most comprehensive in its kind in epilepsy pharmacogenetics. Although it is now possible to screen the entire genome, targeted studies of biologically plausible candidate genes remain a valid approach. Our strategy was to select those genes encoding the major DMEs and targets of three commonly prescribed AEDs, as well as the genes encoding the major brain-expressed voltage-gated sodium channels, which are targets of a broad range of AEDs. We recognize that the gene list is not exhaustive. Also, we did not include genes encoding AED transporters, as this group of genes, with ABCB1 in particular, has been studied extensively and their role in the response to AEDs remains uncertain [4, 9, 10] . Phenotypical data were collected in a retrospective manner, resulting in inherent weaknesses. A proportion of patients may have been misclassified because of confounding factors such as incompliance and drug interactions. This could negatively affect study power. A prospective study design could yield more accurate phenotypes but would require considerable efforts, resources and time to recruit large numbers of patients. Moreover, a prospective design would not entirely eliminate misclassification because of long-term spontaneous fluctuation in drug response, which has been well documented [11] [12] [13] . To reduce potential misclassification, all patients were phenotyped uniformly by a single clinician and using a specialized database. Furthermore, we used rigorous phenotype definitions to obtain relatively extreme phenotypes. The disadvantage of this strategy is that a large proportion of patients remain unclassified. This is especially the case for the AED efficacy analysis. Therefore, some of the results may be false negatives owing to low patient numbers. In our first patient cohort, we identified an association of CYP2C9*2 and *3 alleles with PHT ADRs and an association of a common CNV in GSTM1 with CBZ ADRs.
The CYP2C9 gene encodes one of the major drugmetabolizing cytochrome P450 isoforms. Substantial in vitro data demonstrate that the CYP2C9*2 and *3 alleles result in significant reductions in the metabolism of various CYP2C9 substrates, with *3 showing consistently greater reductions in intrinsic clearance than *2. CYP2C9 accounts for up to 90% of the metabolism of PHT [14] . To our knowledge, our study is the first to demonstrate an association of CYP2C9 variant alleles with ADRs on PHT in a cohort of patients. Single case reports have described associations of low-activity alleles with PHT toxicity [15, 16] . One previous association study systematically assessed the variant CYP2C9*2 and *3 alleles in relation to ADRs on PHT and found no correlation [17] . Although measurement of PHT plasma levels reflects PHT metabolism rates, a CYP2C9 genotyping test could offer the possibility of prospective testing. PHT dosage could then be increased more cautiously in poor metabolizers.
The association of a homozygous GSTM1 deletion with ADRs on CBZ therapy has not been reported before. The GSTM1 gene encodes glutathione S-transferase mu 1. GSTs are involved in the detoxification of reactive CBZ metabolites [18, 19] . Deletion of a GSTM1 allele is present in about 70% of the population. Homozygous deletion, resulting in complete absence of GSTM1 enzyme activity, has a frequency of >50% amongst Caucasians [20] . The GSTM1 deletion has been suggested to play a role in CBZ-and VPA-related hepatotoxicity in Japanese patients [21, 22] . We could not replicate our association in a second patient cohort. Possible confounders such as genotyping error, population stratification and population-specific association were checked for and seem unlikely to be responsible for the non-replication. Although both patient cohorts were phenotyped using the same clinical database, the definitions used for the absence of ADRs on CBZ are slightly different between the two cohorts. However, it seems unlikely that this could explain the non-replication. It is well known that the genetic effect of an association in a first report is often overestimated [23, 24] . Therefore, the most probable explanation for the non-replication is that the size of the second patient cohort, although comparable to that of the first cohort, was too small to detect the association.
Our findings would need to be replicated in an independent large cohort, using the same phenotype definitions. If our results can be confirmed, this could lead to the development of pharmacogenetic tests to be used in clinic. At the moment, it is largely impossible to predict how individual patients will react to a particular AED in terms of seizure control and ADRs. Availability of a test that predicts which AEDs are most likely to be beneficial in a given patient could result in a more rational use of AEDs. Because the effect sizes of individual genetic variants are mostly small, such a test would likely include a number of different genetic variants in several genes, to yield sufficiently high predictive values to be clinically significant [25] .
More generally, pharmacogenetic studies in epilepsy may enhance our understanding of the mechanisms of action of AEDs and the biology of ADRs. This knowledge may be useful in the development of new drugs. Figure S1 . Numbers of patients recruited and excluded. Table S1 . Ethnic origin of 495 patients in the first cohort. Table S2 . Contingency table comparing CYP2C9*2 and CYP2C9*3 genotypes with ADRs on PHT.
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